Efficacy of Guanxinning Injection Combined with Sacubitril/Valsartan in the Treatment of Coronary Heart Disease with Congestive Heart Failure and Effect on Cardiac Function and Myocardial Injury Markers
ZHANG Xiaorui1, LI Jianhua2, LIU Hui2
1. Department of Cardiovascular Medicine, Huaxian Hospital, the First Affiliated Hospital of Xinxiang Medical University, Anyang Henan 456400; 2. Department of Cardiovascular Medicine, the First Affiliated Hospital of Henan Medical University, Xinxiang Henan 453100
Abstract：【Objective】 To investigate the clinical efficacy of Guanxinning Injection combined with Sacubitril/Valsartan in the treatment of coronary heart disease complicated with congestive heart failure and its effects on cardiac function and myocardial injury markers. 【Methods】 A total of 110 patients with coronary heart disease complicated with congestive heart failure admitted to two hospitals from July 2024 to June 2025 were enrolled. The patients were randomly divided into an observation group and a control group using a random number table method, with 55 cases in each group. The control group received Sacubitril/Valsartan on the basis of conventional treatment, while the observation group received Guanxinning Injection in addition to the treatment of the control group. The clinical efficacy, cardiac function indicators [left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD)], myocardial injury markers [N-terminal pro-brain natriuretic peptide (NT-proBNP), cardiac troponin T (cTnT), cardiac troponin I (cTnI)], and the incidence of adverse reactions were compared between the two groups. 【Results】 The total clinical effective rate in the observation group was 96.36%(53/55), which was higher than that in the control group [85.45%(47/55)], and the difference was statistically significant (χ2=3.960, P<0.05). After treatment, LVEF in both groups was higher than that before treatment, while LVEDD and LVESD were shorter than those before treatment; The observation group showed higher LVEF and shorter LVEDD and LVESD compared with the control group, with statistically significant differences (P<0.05). After treatment, the serum levels of NT-proBNP, cTnT, and cTnI in both groups were lower than those before treatment, and these levels in the observation group were lower than those in the control group, with statistically significant differences (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (χ2=0.909, P>0.05). 【Conclusion】 The combination of Guanxinning injection and sacubitril/valsartan demonstrates favorable efficacy in patients with coronary heart disease and congestive heart failure by improving cardiac function and reducing myocardial injury, without increasing adverse reactions.
张小瑞, 李建华, 刘辉. 冠心宁注射液联合沙库巴曲缬沙坦治疗冠心病合并充血性心力衰竭的临床疗效及对患者心功能、心肌损伤指标的影响[J]. 医学临床研究, 2026, 43(6): 903-906.
ZHANG Xiaorui, LI Jianhua, LIU Hui. Efficacy of Guanxinning Injection Combined with Sacubitril/Valsartan in the Treatment of Coronary Heart Disease with Congestive Heart Failure and Effect on Cardiac Function and Myocardial Injury Markers. JOURNAL OF CLINICAL RESEARCH, 2026, 43(6): 903-906.
2026, Vol. 43 
